Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PC-104** is a synthetic pseudoceramide, chemically identified as hydroxypropyl bispalmitamide MEA, designed to mimic the barrier-supporting functions of endogenous stratum-corneum ceramides. It is used topically as a skin-conditioning and barrier-restoring ingredient that increases skin hydration and reduces transepidermal water loss. In a four-week clinical study, PC-104 was administered within a proprietary topical cream also containing palmitamide MEA, glycyrrhetinic acid, and grape seed extract; the combination improved signs and symptoms of mild-to-moderate atopic dermatitis and other pruritic dermatoses. PC-104 originated from Amorepacific pseudoceramide research and was subsequently evaluated in an Exeltis-supported therapeutic cream study.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PC-104.